← ANALYST RATINGS · TIPRANKS
Tarsus Pharmaceuticals (TARS): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $93.20, the highest $105, the lowest $84.00. The average is +36.9% from the last price of $68.07.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $81.00 → $77.00−4.9% | Buy | +13.1% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $80.00 → $77.00−3.7% | Buy | +13.1% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $76.00 → $73.00−3.9% | Hold | +7.2% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $75.00 → $72.00−4.0% | Hold | +5.8% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $81.00 → $78.00−3.7% | Buy | +14.6% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $80.00 → $77.00−3.7% | Buy | +13.1% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $84.00 | Buy | +23.4% | Reiterated | 12.10.26on TipRanks 08:05 | +1.8%next day −4.8% | ↗ |
| Jenna Davidner★★★★★★★★★★#10265 · hits 25% · avg −5.3% | Barclays | $110 | Buy | +61.6% | Reiterated | 09.10.26on TipRanks Oct 12 05:07 | +0.7%next day +1.8% · 5 days −5.0% | ↗ |
| Mazahir Alimohamed★★★★★★★★★★#9079 · hits 50% · avg −1.5% | Oppenheimer | $100 | Buy | +46.9% | Reiterated | 02.10.26on TipRanks 08:30 | −4.0%next day +1.3% · 5 days −0.9% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $116 | Buy | +70.4% | Initiated | 24.09.26on TipRanks 04:35 | +2.3%next day −0.9% · 5 days −0.2% | ↗ |
| Dennis Ding★★★★★★★★★★#2230 · hits 58% · avg +12.3% | Jefferies | $105 | Buy | +54.3% | Reiterated | 08.09.26on TipRanks 13:55 | −3.4%next day −4.6% · 5 days −9.2% | ↗ |
| Lachlan Hanbury Brown★★★★★★★★★★#11394 · hits 35% · avg −5.4% | William Blair | — | Buy | — | Reiterated | 12.08.26on TipRanks 11:05 | +0.5%next day −2.3% · 5 days +5.3% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $100 | Buy | +46.9% | Reiterated | 11.08.26on TipRanks Aug 12 08:15 | +2.8%next day +0.5% · 5 days +2.7% | ↗ |
| Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% | LifeSci Capital | $104 | Buy | +52.8% | Assigned | 08.08.26on TipRanks Aug 7 07:30 | −1.4%next day +4.6% · 5 days +6.4% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $88.00 | Buy | +29.3% | Reiterated | 07.08.26on TipRanks 06:25 | −1.4%next day +4.6% · 5 days +6.4% | ↗ |
| Eddie Hickman★★★★★★★★★★#1243 · hits 64% · avg +28.1% | Guggenheim | $90.00 → $89.00−1.1% | Buy | +30.7% | Reiterated | 21.07.26on TipRanks 21:01 | +0.7%next day +3.0% · 5 days +4.0% | ↗ |
| Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% | Chardan Capital | $105 → $98.00−6.7% | Buy | +44.0% | Reiterated | 24.04.26on TipRanks 13:25 | 0.0%next day −1.0% · 5 days +2.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Tarsus Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $100 at a price of $78.61 (+27.4%); now: $99.56 at $68.07 (+46.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 8 | 7 | 7 | 1 |
| Buy | 8 | 7 | 8 | 5 | 6 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.50 (from $-2.01 to $-0.44). Last quarter: $-0.43.
Sales
Next quarter’s sales estimate — $185M (from $179M to $194M). Last quarter: $174M.
Best top-analyst consensus in the sector · Healthcare
About Tarsus Pharmaceuticals
- CEO: Bobak R. Azamian
- Employees: 370
- 15440 Laguna Canyon Road, Irvine, CA, 92618, US
- www.tarsusrx.com
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Data from the stock’s TipRanks forecast page, read 80 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗